Recombinant adeno-associated viral vectors
(rAAV) are highly versatile gene transfer agents for somatic
transgenic, gene therapy and functional genomicstudies. Derived
from a non-pathogenic virus from the Parvoviridae family,
rAAV vectors can efficiently transfer genes of interest to a broad
range of cell types leading to high levels of stable and long-term
expression after a single application. The lack of immunogenicity
and no known pathogenicity, together with the lowest NIH risk group
category, BL1, make rAAV the vector of choice for many
applications. Moreover, they provide the cleanest system to
alter gene expression in the mammalian brain and other organs in
experimental animal studies. They provide for the ability to
control expression both temporally and spatially, and in
floxed animals, the use of cre recombinase expressing
vectors enables specific cells and tissues to be targeted at any
time during development.
AAV
is now known to have many clades, with over a hundred isolates from
different mammalian species, many sufficiently characterized to
meet criteria as serotypes. Harlan Laboratories
GenscreenTM provides expression vectors for the most
widely used rAAV serotypes in a kit form, which enables
investigators to select the optimal serotype for their specific
application.
In
addition, Harlan Laboratories GenScreenTM has
characterized four completely novel recombinant serotypes which
have unique properties and show enhanced transduction efficiencies
in many cell types in vitro and in vivo. These new
serotypes are also available in a kit form for testing and
optimization.
Additional
Links: